Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 2, 2011, Pages 317-323

  Chang, Myung Hee ^a   Lee, In Kyu ^a   Si, Yoon ^a   Lee, Kyu Sang ^b   Woo, In Sook ^a   Byun, Jae Ho ^c  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

Adjuvant chemotherapy; Colorectal cancer; FOLFOX4; K ras

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CODON; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; ONCOGENE K RAS; OVERALL SURVIVAL; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; RECTUM CANCER; WEAKNESS;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CODON; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; FLUOROURACIL; GENES, RAS; GENETIC ASSOCIATION STUDIES; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 79960923827     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1496-5     Document Type: Article

References (37)

1. Y Jiang ET Kimchi KF Staveley-O'Carroll H Cheng JA Ajani 2009 Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer Cancer 115 3609 3617 19526592 10.1002/cncr.24434 1:CAS:528:DC%2BD1MXhtVOnurjF
2. CS Karapetis S Khambata-Ford DJ Jonker CJ O'Callaghan D Tu NC Tebbutt RJ Simes H Chalchal JD Shapiro S Robitaille TJ Price L Shepherd HJ Au C Langer MJ Moore JR Zalcberg 2008 K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 1757 1765 18946061 10.1056/NEJMoa0804385 1:CAS:528:DC%2BD1cXht12nu77J
3. RG Amado M Wolf M Peeters E Van Cutsem S Siena DJ Freeman T Juan R Sikorski S Suggs R Radinsky SD Patterson DD Chang 2008 Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 1626 1634 18316791 10.1200/JCO.2007.14.7116 1:CAS:528: DC%2BD1cXltlWhsrw%3D
4. HJ Andreyev AR Norman D Cunningham J Oates BR Dix BJ Iacopetta J Young T Walsh R Ward N Hawkins M Beranek P Jandik R Benamouzig E Jullian P Laurent-Puig S Olschwang O Muller I Hoffmann HM Rabes C Zietz C Troungos C Valavanis ST Yuen JW Ho CT Croke DP O'Donoghue W Giaretti A Rapallo A Russo V Bazan M Tanaka K Omura T Azuma T Ohkusa T Fujimori Y Ono M Pauly C Faber R Glaesener AF de Goeij JW Arends SN Andersen T Lovig J Breivik G Gaudernack OP Clausen PD De Angelis GI Meling TO Rognum R Smith HS Goh A Font R Rosell XF Sun H Zhang J Benhattar L Losi JQ Lee ST Wang PA Clarke S Bell P Quirke VJ Bubb J Piris NR Cruickshank D Morton JC Fox F Al-Mulla N Lees CN Hall D Snary K Wilkinson D Dillon J Costa VE Pricolo SD Finkelstein JS Thebo AJ Senagore SA Halter S Wadler S Malik K Krtolica N Urosevic 2001 Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study Br J Cancer 85 692 696 11531254 10.1054/bjoc.2001.1964 1:CAS:528:DC%2BD3MXns1yktr8%3D (Pubitemid 32929467)
5. A Conlin G Smith FA Carey CR Wolf RJ Steele 2005 The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma Gut 54 1283 1286 15843421 10.1136/gut.2005.066514 1:CAS:528:DC%2BD2MXhtVegsrvL (Pubitemid 41192491)
6. S Markowitz JD Hines J Lutterbaugh L Myeroff W Mackay N Gordon Y Rustum E Luna J Kleinerman 1995 Mutant K-ras oncogenes in colon cancers Do not predict Patient's chemotherapy response or survival Clin Cancer Res 1 441 445 9816002 1:CAS:528:DyaK2sXht1Cqu7o%3D
7. H Bouzourene P Gervaz JP Cerottini J Benhattar P Chaubert E Saraga S Pampallona FT Bosman JC Givel 2000 p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer Eur J Cancer 36 1008 1015 10885605 10.1016/S0959-8049(00)00036-8 1:CAS:528:DC%2BD3cXjsVCqsLk%3D (Pubitemid 30316426)
8. R Tang JY Wang CW Fan KC Tsao HH Chen CM Wu JS Chen CR Changchien LL Hsieh 2004 p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy Cancer Lett 210 101 109 15172127 10.1016/j.canlet.2004.01.006 1:CAS:528:DC%2BD2cXksVCisbs%3D (Pubitemid 38692594)
9. T Andre P Colin C Louvet E Gamelin O Bouche E Achille N Colbert C Boaziz P Piedbois N Tubiana-Mathieu A Boutan-Laroze M Flesch M Buyse A de Gramont 2003 Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial J Clin Oncol 21 2896 2903 12885807 10.1200/JCO.2003.10. 065 1:CAS:528:DC%2BD2cXpsVKjtrk%3D (Pubitemid 46621839)
10. P Comella R Casaretti C Sandomenico A Avallone L Franco 2009 Role of oxaliplatin in the treatment of colorectal cancer Ther Clin Risk Manag 5 229 238 19436599 10.2147/TCRM.S3583
11. T Andre C Boni M Navarro J Tabernero T Hickish C Topham A Bonetti P Clingan J Bridgewater F Rivera A de Gramont 2009 Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial J Clin Oncol 27 3109 3116 19451431 10.1200/JCO.2008.20.6771 1:CAS:528:DC%2BD1MXhtFWitbzF
12. Colon Cancer (2010) NCCN Clinical Practice Guidelines in Oncology
13. MJ O'Connell 2009 Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in J Clin Oncol 27 3082 3084 19451420 10.1200/JCO.2009.22.2919
14. DJ Ahnen P Feigl G Quan C Fenoglio-Preiser LC Lovato PA Bunn Jr G Stemmerman JD Wells JS Macdonald FL Meyskens Jr 1998 Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study Cancer Res 58 1149 1158 9515799 1:CAS:528: DyaK1cXhvV2rsro%3D (Pubitemid 28183202)
15. WA Bleeker VM Hayes A Karrenbeld RM Hofstra E Verlind J Hermans S Poppema CH Buys JT Plukker 2001 Prognostic significance of K-ras and TP53 mutations in the role of adjuvant chemotherapy on survival in patients with Dukes C colon cancer Dis Colon Rectum 44 358 363 11289281 10.1007/BF02234733 1:STN:280:DC%2BD3M7pvFyrsw%3D%3D (Pubitemid 32226324)
16. S Ogino JA Meyerhardt N Irahara D Niedzwiecki D Hollis LB Saltz RJ Mayer P Schaefer R Whittom A Hantel AB Benson 3rd RM Goldberg MM Bertagnolli CS Fuchs 2009 KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803 Clin Cancer Res 15 7322 7329 19934290 10.1158/1078-0432.CCR-09-1570 1:CAS:528:DC%2BD1MXhsFSnu73F
17. HC Moore DG Haller 1999 Adjuvant therapy of colon cancer Semin Oncol 26 545 555 10528903 1:CAS:528:DyaK1MXntFOktbw%3D (Pubitemid 29483280)
18. SD Richman MT Seymour P Chambers F Elliott CL Daly AM Meade G Taylor JH Barrett P Quirke 2009 KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial J Clin Oncol 27 5931 5937 19884549 10.1200/JCO.2009.22.4295 1:CAS:528:DC%2BC3cXhtVWisL4%3D
19. GM Nash M Gimbel AM Cohen ZS Zeng MI Ndubuisi DR Nathanson J Ott F Barany PB Paty 2009 Kras mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer Ann Surg Oncol 8 8
20. V Bazan M Migliavacca I Zanna C Tubiolo N Grassi MA Latteri M La Farina I Albanese G Dardanoni S Salerno RM Tomasino R Labianca N Gebbia A Russo 2002 Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype Ann Oncol 13 1438 1446 12196370 10.1093/annonc/mdf226 1:STN:280:DC%2BD38vjvVGisQ%3D%3D
21. HE Oh SJ Cho NH Won D Lee I Kim BW Yeom 2001 K-ras gene mutations and expression of K-ras, p16, Cyclin D1 and p53 in synchronous lesions of the colon adenoma carcinoma sequences The Korean Journal of Pathology 35 291 298
22. CH Jeon HI Lee IH Shin JW Park 2008 Genetic alterations of APC, K-ras, p53, MSI, and MAGE in Korean colorectal cancer patients Int J Colorectal Dis 23 29 35 17704924 10.1007/s00384-007-0373-0 (Pubitemid 350142357)
23. S Anwar IM Frayling NA Scott GL Carlson 2004 Systematic review of genetic influences on the prognosis of colorectal cancer Br J Surg 91 1275 1291 15382104 10.1002/bjs.4737 1:CAS:528:DC%2BD2cXps1Kmurk%3D (Pubitemid 39331451)
24. MJ Ahn BB Park JS Ahn SW Kim HT Kim JS Lee JH Kang JY Cho HS Song SH Park CH Sohn SW Shin JH Choi CS Ki CK Park AJ Holmes PA Janne K Park 2008 Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer? Clin Cancer Res 14 3860 3866 18559606 10.1158/1078-0432.CCR-07-4608 1:CAS:528:DC%2BD1cXntlWrt7w%3D
25. L Klampfer LA Swaby J Huang T Sasazuki S Shirasawa L Augenlicht 2005 Oncogenic Ras increases sensitivity of colon cancer cells to 5-FU-induced apoptosis Oncogene 24 3932 3941 15856030 10.1038/sj.onc.1208552 1:CAS:528:DC%2BD2MXks1Ogu7Y%3D (Pubitemid 40896405)
26. J Nemunaitis J Cox W Meyer A Courtney G Mues 1997 Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5-fluorouracil (5-FU) Am J Clin Oncol 20 527 529 9345343 10.1097/00000421-199710000-00020 1:STN:280: DyaK1c%2FgsFWmtg%3D%3D (Pubitemid 27444356)
27. G Smith FA Carey J Beattie MJ Wilkie TJ Lightfoot J Coxhead RC Garner RJ Steele CR Wolf 2002 Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer Proc Natl Acad Sci USA 99 9433 9438 12093899 10.1073/pnas.122612899 1:CAS:528:DC%2BD38XlsVGgt78%3D (Pubitemid 34764631)
28. G Gnanasampanthan H Elsaleh K McCaul B Iacopetta 2001 Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer J Pathol 195 543 548 11745689 10.1002/path.990 1:CAS:528: DC%2BD38XjvVemtA%3D%3D (Pubitemid 34030791)
29. K Harada S Hiraoka J Kato J Horii H Fujita K Sakaguchi Y Shiratori 2007 Genetic and epigenetic alterations of Ras signalling pathway in colorectal neoplasia: analysis based on tumour clinicopathological features Br J Cancer 97 1425 1431 17923875 10.1038/sj.bjc.6604014 1:CAS:528:DC%2BD2sXht1yrsr7M (Pubitemid 350114780)
30. E Miranda A Destro A Malesci E Balladore P Bianchi E Baryshnikova G Franchi E Morenghi L Laghi L Gennari M Roncalli 2006 Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer Br J Cancer 95 1101 1107 16969349 10.1038/sj.bjc.6603337 1:CAS:528:DC%2BD28XhtVyitbnL (Pubitemid 44606839)
31. OK Glebov LM Rodriguez K Nakahara J Jenkins J Cliatt CJ Humbyrd J DeNobile P Soballe R Simon G Wright P Lynch S Patterson H Lynch S Gallinger A Buchbinder G Gordon E Hawk IR Kirsch 2003 Distinguishing right from left colon by the pattern of gene expression Cancer Epidemiol Biomarkers Prev 12 755 762 12917207 1:CAS:528:DC%2BD3sXmt1els74%3D (Pubitemid 36993166)
32. SR Calcagno S Li M Colon PA Kreinest EA Thompson AP Fields NR Murray 2008 Oncogenic K-ras promotes early carcinogenesis in the mouse proximal colon Int J Cancer 122 2462 2470 18271008 10.1002/ijc.23383 1:CAS:528:DC%2BD1cXltlaiurw%3D (Pubitemid 351590478)
33. K Turaga D Shibata 2009 K-Ras and MSI: potential markers of both patient prognosis and treatment efficacy Ann Surg Oncol 20 20
34. S Popat R Hubner RS Houlston 2005 Systematic review of microsatellite instability and colorectal cancer prognosis J Clin Oncol 23 609 618 15659508 10.1200/JCO.2005.01.086 1:CAS:528:DC%2BD2MXitVartLY%3D (Pubitemid 46224239)
35. W Dempke W Voigt A Grothey BT Hill HJ Schmoll 2000 Cisplatin resistance and oncogenes-a review Anticancer Drugs 11 225 236 10898536 10.1097/00001813- 200004000-00001 1:CAS:528:DC%2BD3cXkvVygu7k%3D (Pubitemid 30416950)
36. E Levy C Baroche JM Barret C Alapetite B Salles D Averbeck E Moustacchi 1994 Activated ras oncogene and specifically acquired resistance to cisplatin in human mammary epithelial cells: induction of DNA cross-links and their repair Carcinogenesis 15 845 850 8200085 10.1093/carcin/15.5.845 1:CAS:528: DyaK2cXkt1KntL8%3D (Pubitemid 24156879)
37. CK Youn MH Kim HJ Cho HB Kim IY Chang MH Chung HJ You 2004 Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents Cancer Res 64 4849 4857 15256455 10.1158/0008-5472.CAN-04-0348 1:CAS:528:DC%2BD2cXls1OmsbY%3D (Pubitemid 38924529)